327
Views
6
CrossRef citations to date
0
Altmetric
Original

LONG-TERM INTRAVENOUS CALCITRIOL IN SECONDARY HYPERPARATHYROIDISM: THE ROLE OF TECHNETIUM-99M-MIBI SCINTIGRAPHY IN PREDICTING THE RESPONSE TO TREATMENT

, M.R.C.P., , F.R.C.P., , M.R.C.P., , FACARZT, , ABIM, , CES, , , F.R.C.P. & , F.R.C.P. show all
Pages 165-173 | Published online: 07 Jul 2009

REFERENCES

  • Salem M.M. Hyperparathyroidism in the Hemodialysis Population: A Survey of 612 Patients. Am. J. Kidney Dis. 1997; 29: 862–865
  • Malberti F., Corradi B., Cosci P., Calliada F., Marcelli D., Imbasciati E. Long-Term Effects of Intravenous Calcitriol Therapy on the Control of Secondary Hyperparathyroidism. Am. J. Kidney Dis. 1996; 28: 704–712
  • Fukagawa M., Kitaoka M., Yi H., Fukuda N., Matsumoto T., Ogata E., Kurokawa K. Serial Evaluation of Parathyroid Size by Ultrasonography is Another Useful Marker for the Long-Term Prognosis of Calcitriol Pulse Therapy in Chronic Dialysis Patients. Nephron. 1994; 68: 221–228
  • Quarles L.D., Yohay D.A., Carrol B.A. Prospective Trial of Pulse Oral Versus Intravenous Calcitriol Treatment of Hyperparathyroidism in ESRF. Kidney Int. 1994; 45: 1710–1721
  • O’ Doherty M.J., Kettle A.G., Wells P., Collins R.E.C., Coakley A.J. Parathyroid Imaging with Technetium-99m-Sestamibi: Preoperative Localization and Tissue Uptake Studies. J. Nuc. Med. 1992; 33: 313–318
  • Piwinica-Worms D., Holman B.L. Noncardiac Application of Hexakis Alkylisonitrile Technetium-99m Complexes. J. Nuc. Med. 1990; 31: 1166–1167
  • Piga M., Bolasco P., Satta L., Altieri P., Loi G., Nicolosi A., Tarquini A., Mariotti S. Double-Phase Parathyroid Technetium-99m-MIBI Scintigraphy to Identify Functional Autonomy in Secondary Hyperparathyroidism. J. Nuc. Med. 1996; 37: 565–569
  • Ambrossoni P., Heuguerot C., Olaizola I. Can We Use 99mTc-MIBI in Functional Studies of the Parathyroid Gland?. Nephrol. Dial. Transplant. 1998; 13(suppl 3)33–36
  • Rassoul Z., Mousa D., Abdur, Rehman M. Serum Parathyroid Hormone Suppression by Intravenous 1,25-dihydroxyvitamin D3 in Patients on Maintenance Hemodialysis. Am. J. Nephrol. 1995; 15: 507–511
  • Slatopolsky E., Weerts C., Thielan J., Horst R., Harter H., Martin K.J. Marked Suppression of Secondary Hyperparathyroidism by Intravenous Administration of 1,25-dihydroxycholecalciferol in Uremic Patients. J. Clin. Invest. 1984; 74: 2136–2143
  • Dunlay R., Rodriguez M., Felsenfeld A.J., Llach F. Direct Inhibitory Effect of Calcitriol on Parathyroid Function (Sigmoidal Curve) in Dialysis. Kidney Int. 1989; 36: 1093–1098
  • Delmez J.A., Tindira C., Grooms P., Dusso A., Windus D.W., Slatopolsky E. Parathyroid Hormone Suppression by Intravenous 1,25-Dihydroxyvitamin D. J. Clin. Invest. 1989; 83: 1349–1355
  • Andress D.L., Norris K.C., Coburn J.W., Slatopolsky E.A., Sherrard D.J. Intravenous Calcitriol in the Treatment of Refractory of Osteitis Fibrosa of Chronic Renal Failure. N. Engl. J. Med. 1989; 321: 274–279
  • Malberti F., Surian M., Cosci P. Effect of Chronic Intravenous Calcitriol on Parathyroid Function and Set Point of Calcium in Dialysis Patients with Refractory Secondary Hyperparathyroidism. Nephrol. Dial. Transplant. 1992; 7: 822–828
  • Dressler R., Laut J., Lynn R.I., Ginsberg N. Long-Term High Dose Intravenous Calcitriol Therapy in End-Stage Renal Disease Patients with Severe Secondary Hyperparathyroidism. Clin. Nephrol. 1995; 43: 324–331
  • Fukuda N., Tanaka H., Tominaga Y., Fukagawa M., Kurokawa K., Seino Y. Decreased 1,25-Dihydroxyvitamin D3 Receptor Density is Associated with a More Severe Form of Parathyroid Hyperplasia in Chronic Uremic Patients. J. Clin. Invest. 1993; 92: 1436–1443
  • Chesser A.M.S., Carroll M.C., Lightowler C., Macdougal I.C., Britton K.E., Baker L.R.I. Technetium-99m Methoxy Isobutyl Isonitrile (MIBI) Imaging of the Parathyroid Glands in Patients with Renal Failure. Nephrol. Dial. Transplant. 1997; 12: 97–100
  • Torregrosa J.V., Palomar M.R., Pons F., Sabater L., Gilabert R., Llovera J., Fernandez-Cruz L. Has Double-Phase MIBI Scintigraphy Usefulness in the Diagnosis of Hyperparathyroidism?. Nephrol. Dial. Transplant. 1998; 13(suppl. 3)37–40

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.